Print page |
Email page
| 
Download PDF
|
Add to briefcase
« Previous Release | Next Release »
"Our newly approved dermatology indication opens two interesting new
markets to Oculus — atopic dermatitis, which afflicts 15 million
U.S. patients, and radiation dermatitis, with over one million U.S.
patients. The use of the proprietary Microcyn Technology for these
challenging skin afflictions is truly a unique approach and adds both
depth and breadth to Oculus' dermatology product portfolio," said
About Atopic Dermatitis
More than 15 million patients have symptoms of atopic dermatitis, characterized by itchy skin, which can lead to rash, redness, swelling, crusting and scaling. The disease affects up to 20 percent of infants and young children, who continue to have symptoms as adults with significant impact on their quality of life. The exact cause is unknown, but genetics are considered a key factor.
In a 2009 GlobalData study, it was estimated the global atopic
dermatitis therapeutics market delivered revenues of
About Radiation Dermatitis
Radiation dermatitis is an unintended and often unavoidable skin
reaction commonly experienced by patients receiving radiation therapy as
part of their cancer treatment. This side effect, caused by radiation
passing through skin cells, is often unpleasant and painful and may
contribute to poor quality of life in cancer patients. In some cases,
radiation dermatitis may become so severe as to necessitate interruption
or cessation of radiation therapy. A wide variety of products have been
used to treat radiation dermatitis with little or no evidence to support
their use. According to estimates from the
About
Forward-Looking Statements
Except for historical information herein, matters set forth in this
press release are forward-looking within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of
1995, including statements about the Company's commercial and technology
progress and future financial performance. These forward-looking
statements are identified by the use of words such as "opens," "adds"
and "plan," among others. Forward-looking statements in this press
release are subject to certain risks and uncertainties inherent in the
Company's business that could cause actual results to vary,
including such risks that regulatory clinical and guideline developments
may change, scientific data may not be sufficient to meet regulatory
standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient
settings, protection offered by the Company's patents and patent
applications may be challenged, invalidated or circumvented by its
competitors, the available market for the Company's products will not be
as large as expected, the Company's products will not be able to
penetrate one or more targeted markets, revenues will not be sufficient
to fund further development and clinical studies, the Company may not
meet its future capital needs, and its ability to obtain additional
funding, as well as uncertainties relative to varying product
formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other risks
detailed from time to time in the Company's filings with the
Oculus, Epicyn and Microcyn Technology are trademarks or registered
trademarks of
Media and
Investor Contact:
dmcfadden@oculusis.com
Director
of Public and Investor Relations
Source:
News Provided by Acquire Media